Cytori Therapeutics (CYTX) Jumps: Stock Moves Up 10%

Cytori Therapeutics, Inc. CYTX was a big mover last session, as its shares rose roughly 10% on the day. The upside was owing to the receipt of a conditional approval from the FDA for alopecia trial by Cytori's licensee – Kerastem Technologies. This also led to far more shares changing hands than in a normal session. Yesterday's rally reverses the downtrend for the company, as the stock is now down over 21% in the past one-month time frame.

Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cytori Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is AMAG Pharmaceuticals, Inc. AMAG with a Zacks Rank #1 (Strong Buy).

Is CYTX going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CYTORI THERAPEU CYTX: Free Stock Analysis Report
 
AMAG PHARMA INC AMAG: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!